PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
J Sex Med. Author manuscript; available in PMC Jan 7, 2012.
Published in final edited form as:
PMCID: PMC3253142
NIHMSID: NIHMS328555
Priapism in Sickle Cell Disease: A Hematologist’s Perspective
Gregory J. Kato
Gregory J. Kato, Sickle Cell Vascular Disease Section, Cardiovascular and Pulmonary Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892;
Corresponding Author: Gregory J Kato, MD, National Institutes of Health, 9000 Rockville Pike, MSC 1476, Building 10-CRC, Room 5-5140, Bethesda, MD 20892-1476, Phone: 301-451-8497, Fax: 301-451-7091, gkato/at/mail.nih.gov
Introduction
Priapism is a familiar problem to hematologists, well known for its association with sickle cell disease. It also occurs in a variety of other hematological illnesses, nearly all forms of congenital hemolytic anemia, including other hemoglobinopathies and red blood cell membranopathies and enzymopathies.
Aim
Provide urologists with a comprehensive review of priapism in sickle cell disease, with an emphasis on the perspective of a practicing hematologist.
Methods
Medline searches through July 2010 were conducted using the terms priapism, erectile dysfunction, and sickle cell.
Main Outcome Measure
Expert opinion was based on review of the medical literature related to this subject matter.
Results
In men with sickle cell disease, large epidemiological studies have linked the risk of priapism to clinical markers of the severity of intravascular hemolysis. Extracellular hemoglobin and arginase released during hemolysis has been implicated in reducing nitric oxide bioavailability, although the relevance of hemolysis to vascular dysfunction has been challenged by some scientists. Consistent with the role of impairment of the nitric oxide axis, mice genetically deficient in nitric oxide production have also been shown to develop priapic activity. Provocative new data indicates that hemolysis-linked dysregulation of adenosine signaling in the penis contributes to priapism in sickle cell mice. Serious questions have arisen regarding the efficacy of mainstays of textbook dogma for treatment of acute severe priapism, including intravenous fluids, alkalinization and exchange transfusion, and there is increasing acceptance for early aspiration and irrigation of the corpus cavernosum.
Conclusions
For sickle cell patients with recurrent priapism, there is very limited evidence for a medical prophylaxis role for hydroxyurea, etilefrine, pseudoephedrine, leuprolide, sildenafil, and other agents. Recent publications have highlighted nitric oxide and adenosine signal transduction pathways as worthy of additional research. Research and clinical management of sickle cell priapism is strengthened by multidisciplinary collaboration between hematologists and urologists.
Keywords: Priapism, Ischemic Priapism, Stuttering Priapism, Erectile Dysfunction, Sickle cell, Hematology and Priapism
The year 2010 marks the centenary of the first English language publication on sickle cell disease (SCD). In this case report, published in the Archives of Internal Medicine, photomicrographs of elongated red blood cells were presented by Dr. James B. Herrick, who coined the term “sickle-shaped red blood corpuscles” in the title of the manuscript.1 The first report of priapism in patients with SCD is attributed to Dawson in 1939.2 The next 23 years of progress were summarized in a 1962 publication of two new cases, survey of 24 cases from 13 large hospitals, and literature review of 33 cases by renowned sickle cell disease clinician Dr. Roland B. Scott and his colleagues, who observed that “treatment is symptomatic and generally unsatisfactory; however, needle aspirations of the corpora cavernosa appear to yield the most satisfactory results.”3
Although priapism has achieved the highest level of notoriety in SCD, it also has been reported in many other hematological disorders. Priapism also has been reported in patients with leukemia, multiple myeloma, thalassemia and other hemolytic anemias that will be discussed in more detail below.4 This observation may help to understand potential pathways perturbed in priapism. Priapism also is occasionally seen in patients without any known hematological dyscrasia.5
Polymerization of hemoglobin S
SCD is fundamentally a disorder of polymerization of hemoglobin S (HbS), a mutant version of adult hemoglobin that involves a single amino acid change in the beta chain. SCD is known as the “first molecular disease” due to the finding by Nobel laureate Linus Pauling that the hemoglobin from patients with SCD migrates anomalously on gel electropheresis.6 The nucleotide mutation in the beta-globin messenger RNA that gives rise to that change also among the first base-pair alterations reported in human disease.7 Polymerization of HbS causes stiffness of red cells, which is particularly important to the flow of blood, because red cells are larger than the capillaries through which they must flow. This impairment of red cell rheology occurs even at levels of HbS polymerization insufficient to cause the characteristic shape distortion that give SCD its name.
Cellular adhesion
Other investigators have also published evidence that red cells, white blood cells, and platelets are more adhesive to vascular endothelium in SCD. They have promoted the additional concept that these adhesive events, especially in the post-capillary venules, add to the vascular occlusion imposed by noncompliant red cells.8, 9 Expression of cell surface adhesion molecules is driven by immature blood cells and inflammatory cytokines. These pathways have been worked out in very elegant detail in mouse models of sickle cell disease, but more confirmatory studies are needed in human patients with SCD. These ideas have led to clinical trials of anti-adhesive therapy in patients with SCD.
Vascular dysfunction
Both of the components of the blood vessel wall, the vascular endothelium and vascular smooth muscle, develop pathology in SCD that may contribute to vasculopathy or coagulopathy. Patients with SCD have blunted vasodilatory responses to nitric oxide (NO), the critical mediator of vascular homeostasis.1012 Similarly blunted responses to NO are seen in the SCD mouse.13, 14 Patients with SCD express high levels of endothelial activation markers,1518 and hemostatic activation of platelets and coagulation factors.19 Many elements of this vascular dysfunction overlap with the pathophysiology seen in atherosclerosis or diabetic vasculopathy.20, 21
Complications unique to SCD
There are a number of classical complications of SCD that are not seen in any other disease state. These include the vaso-occlusive pain crisis, also called the acute pain episode. These painful episodes usually are causes by ischemia or infarction of the bone marrow due to vaso-occlusion. They are often treated in the hospital with intravenous hydration and opioids, although this treatment is essentially palliative until self resolution occurs in several days. The incidence of severe painful episodes is often reduced by prophylactic chronic administration of hydroxyurea, provided it is prescribed at adequate dosages and properly supervised. A second unique complication is the acute chest syndrome, a common final pathway of acute lung injury in SCD that resembles acute respiratory distress syndrome. It may be triggered by pneumonia, pulmonary vaso-occlusion, or most commonly by embolization to the lung of infarcted bone marrow, overlapping in several ways the fat embolization syndrome seen in femur fracture patients without SCD. Acute chest syndrome causing hypoxia resolves most quickly with simple or exchange blood transfusion and attentive supportive care. Occasionally seen SCD complications include splenic or hepatic sequestration crisis. SCD patients can suffer acute infarctions of virtually any organ in the body.
Complications Not Unique to SCD
There are several commonly occurring complications of SCD that are also seen in other disorders, including priapism, leg ulcers, pulmonary hypertension, stroke and avascular necrosis of the femoral head. All of these complications are seen at unusually high rates in SCD, clearly implicating SCD as a major risk factor. However, these complications are most often reported in the absence of SCD, suggesting both that sickling is not required for their development, but conversely that sickling likely may contribute to these complications.
Priapism is not unique to SCD
Priapism has been reported in patients with a wide variety of hemolytic anemias beside SCD (Table 1), including thalassemia,2228 hereditary spherocytosis, paroxysmal nocturnal hemoglobinuria, unstable hemoglobin disorders,2931 glucose-6 phosphate dehydrogenase deficiency,32, 33 glucose-6 phosphate isomerase deficiency,34 and congenital dyserythropoietic anemia.35 In many of these cases, the onset of priapism followed splenectomy, leading to the suggestion that asplenia might be a risk factor for priapism.36, 37 Asplenia, a common feature of SCD, promotes thrombocytosis and leukocytosis. In patients with hemolytic anemia, asplenia is also associated with decreased extravascular hemolysis, partially offset by increased intravascular hemolysis, resulting in higher levels of extracellular plasma hemoglobin which might scavenge NO, higher levels of plasma microparticles, known to be pro-thrombotic, and higher levels of phosphatidylserine-externalized red cells, which are more adhesive.38 The prevalence of leg ulcers and pulmonary hypertension in SCD correlate with markers of hemolytic severity, potentially implicating decreased NO bioavailability, asplenia and hemostatic activation in their etiology.39 Similar to the case of priapism, leg ulcers and pulmonary hypertension have been reported in association with a wide variety of hemolytic anemias other than SCD.40
Table 1
Table 1
Hemolytic anemias in which priapism has been reported.
Role of hemolysis in priapism, leg ulcers and pulmonary hypertension
An important consequence of HbS polymerization is premature breakdown of the red cell, which in SCD commonly survive in the circulation only about one-sixth the normal 120-day red cell lifespan. Many publications present data implicating scavenging of NO by hemoglobin released from intravascular lysis of red blood cells in SCD,41, 42 compounded by depletion of arginine, the obligate substrate for NO synthase, by arginase-1 also released from red cells during hemolysis.43 NO may also be scavenged by reactive oxygen species that are abundantly produced in SCD,44 contributing to robust oxidative stress, further exacerbated by the oxidant properties of free heme and iron-catalyzed Fenton reactions.45, 46 Levels of endogenous inhibitors of NO synthase are also found in the plasma from SCD patients at triple the level of healthy control subjects.22, 47 Most of these markers also correlate with leg ulceration,48 and with echocardiographic estimates of high pulmonary artery pressure, implying a role for hemolysis-linked NO deficiency in pulmonary hypertension, a life-limiting complication of SCD.49, 50
The existence of hemolysis-induced impairment of NO deficiency in SCD has been challenged.51 Bunn and colleagues have suggested that the degree of intravascular hemolysis in SCD is insufficient to produce clinically significant NO deficiency. They concede that the degree of intravascular hemolysis in at least one hemolytic anemia, paroxysmal nocturnal hemoglobinuria (PNH), likely promotes NO scavenging and deficiency. They report no known link of PNH to priapism, although such a report has been published.52 They note that any role of NO scavenging in priapism in hemolytic anemias must be complex. Consistent with their caveat, erectile dysfunction is far more common than priapism in PNH,53 and priapism appears to be more common in SCD than erectile dysfunction.54, 55
Clinical epidemiology
In Pohl’s 1986 literature review of 230 cases of priapism, SCD accounted for 11% of cases,56 and as high as 67% of the cases in Winter’s 1988 series of 105 patients with priapism.57 Mantadakis and colleagues found that 29% of male children and adolescents with SCD reported priapism, and projected that up to 89% of SCD males would experience priapism by age 20 years.58 Priapism is reported to be markedly less frequent in Saudi SCD males, attributed to genetically determined high levels of fetal hemoglobin, which generally attenuates SCD complications.59 Greeks with SCD also have low rates of priapism, unrelated to α-thalassemia trait or elevated fetal hemoglobin levels.60 In the Cooperative Study of Sickle Cell Disease, 273 males with a history of priapism had significantly lower levels of hemoglobin than 979 SCD males without priapism.61 They also had higher levels of serum lactate dehydrogenase, bilirubin, and aspartate aminotransferase; and higher reticulocyte counts, all markers of more severe hemolysis in SCD males with priapism, compared to those without priapism (Table 2). White blood cell and platelet counts were also higher in those with a history of priapism. Fetal hemoglobin levels were not different. In a separate study of 78 adult SCD males at the National Institutes of Health, priapism was most prevalent in those with steady state levels of LDH above 511 IU/L.62 Although these results from the United States supports a relationship of priapism to hemolytic severity, but not fetal hemoglobin level, these results are contrasted by a report of 23 SCD males in Nigeria with priapism who manifested higher hematocrit levels and lower fetal hemoglobin levels than those without priapism.63 Coinheritance of α-thalassemia trait, which reduces hemolysis, is protective against priapism in the U.S. population.61 Priapism is associated with certain other clinical manifestations of SCD, such as ischemic stroke, avascular necrosis, acute chest syndrome, acute painful episodes, leg ulcers, chronic renal failure and chronic lung disease.61, 64, 65 Priapism is more prevalent in adult males with SCD who have high tricuspid regurgitant velocity, an echocardiographic marker of high pulmonary artery pressure.49 These studies indicate that SCD males with priapism have a high risk of more severe additional complications of SCD.
Table 2
Table 2
Risk factors and protective factors for sickle cell priapism.
Genetic epidemiology
Priapism in males with SCD has been associated with several genetic markers in two studies (Table 3). Klotho, a membrane protein that regulates nitric oxide synthase, was associated with priapism in SCD.66 This result was not replicated in another smaller study, but several other significant associations were found. These included the transforming growth factor β receptor-3, the cell membrane water channel aquaporin-1, the blood clot stabilizing enzyme Factor XIII, and the integrin αV.67 This integrin is a subunit of the αV3 endothelial adhesion molecule that is believed to bind to sickle erythrocytes to endothelium via intermediary proteins thrombospondin, von Willebrand factor and ICAM-4.9, 68 These interesting genetic associations remain to be validated in a replication cohort.
Table 3
Table 3
Preliminary genetic associations with sickle cell priapism.
Additional evidence linking NO deficiency to priapism
Transgenic and knockout mice have provided additional support that a disordered NO pathway can be at least one cause of priapism (Table 4). Mice that are genetically deficient in endothelial NO synthase develop spontaneous priapic activity.69 The frequency of priapic activity is even greater in the mouse doubly deficient in both endothelial and neuronal NO synthase.70 This is an apparent paradox, since NO deficiency might be predicted to result in erectile dysfunction, which is seen in the mouse deficient in protein kinase G, an important mediator of NO activity exerted via the cyclic guanosine monophosphate (cGMP) signal transduction.71 The mechanism for NO deficiency-induced priapism is a chronic down-regulation of phosphodiesterase-5 (PDE5), the critical regulator of penile vascular homeostasis.70 The same down-regulation of PE5 is observed in penile tissue from the SCD mouse, supporting the physiological effect of NO deficiency in SCD.70, 72, 73 This inhibition of PDE5 expression functionally mimics the effect of the erection-facilitating PDE5 inhibitors, such as sildenafil. NO pathways in priapism and erectile dysfunction remain complex and incompletely understood, with more investigation remaining to be done. These and other mechanistic pathways will be reviewed in more detail in an accompanying manuscript by Dr. Trinity Bivalacqua.
Table 4
Table 4
Mechanistic pathways potentially involved in sickle cell priapism.
Adenosine pathways in sickle cell priapism
Recent data in animal models has implicated adenosine pathways in priapism (Table 4). Adenosine deaminase (ADA) deficient mice and SCD mice develop high levels of adenosine in the penis, associated with priapic activity, which is reversed by systemic administration of or ex vivo incubation with ADA enzyme.74, 75 Evidence suggests that the effect is mediated via the adenosine A2B receptor. High penile concentration of adenosine is also associated with penile fibrosis, a serious end stage of priapism.76 The applicability of this pathway to human priapism must be viewed with caution until human investigations are performed, because priapism has never been reported in humans with ADA deficiency, although the efficacy of enzyme replacement therapy (or frequent early lethality without ADA enzyme replacement) might account for this.
Management of mild priapism
SCD patients often report that light exercise is effective in terminating mild episodes of priapism. Other self-treatment approaches reported by patients have included voiding, opioid and nonsteroidal analgesics, ejaculation, or a warm bath or shower.58, 77, 78 These are all relatively safe approaches to consider in mild episodes of less than four hours duration.
Severe acute priapism episodes: longstanding unsupported dogma
Hematology and urology textbooks continue without reservation to prescribe for severe priapism episodes intravenous hydration, sodium bicarbonate to alkalinize the urine, and exchange transfusion (Table 5). These recommendations have been printed and reprinted for half a century without objective published evidence of efficacy. More recently, published opinion has begun to question this textbook dogma, including the directive of exchange transfusion.79 Not only is the efficacy of emergency exchange transfusion for priapism in question, but there have been reports of acute neurological complications in this setting.80, 81 In my own opinion based on literature reviews and 25 years of experience, treatment has advanced little since the 1962 observation of Dr. Scott cited in the first paragraph of this review. In severe acute priapism, the rite of administration of these usually futile treatments often serves simply to delay definitive aspiration of the penis, which in my experience is usually dramatically effective. This has been best documented by Mantadakis and colleagues from Children’s Medical Center Dallas.78, 82 An accompanying review article in this issue by Dr. Gregory Broderick discusses urological management of acute sickle cell priapism in more detail.
Table 5
Table 5
Medical management of sickle cell priapism.
Medical prevention strategies
There are no clear evidence-based guidelines in this area, only anecdotal experiences, some of which are published, and these have been reviewed in detail.78 There is some limited experience with the use of hydroxyurea for priapism prevention.83, 84 A strong advantage of a therapeutic trial of hydroxyurea in a SCD patient is that the drug has been demonstrated to reduce pain complications and prolong lifespan in adults with symptomatic SCD,85, 86 so that there may be substantial likelihood of additional collateral benefit to the patient. Hydroxyurea is the only drug approved by the FDA specifically for SCD, and its effectiveness is only well characterized when titrated to maximum tolerated dose. As an alternative or additional strategy, some experienced clinicians, including this author, have advocated a therapeutic trial of oral pseudoephedrine 30 – 60 mg at bedtime.78
Paradoxically, sildenafil has been reported in small series to be of prophylactic benefit in sickle cell and thalassemia priapism.8789 Animal data suggests that sildenafil restores deficient production of PDE5 in the penis.70 However, it is difficult to recommend sildenafil for this purpose until a clinical trial has been completed. Another prophylactic treatment with multiple anecdotal successes is injectable leuprolide, the gonadotropin releasing hormone antagonist.78, 90 However, extended use of leuprolide runs a substantial risk of longstanding hypogonadism, and priapism often returns immediately with its discontinuation.78 Diethylstilbestrol showed some efficacy in a small clinical trial, but is rarely used for this purpose due to its feminizing side effects.91 Etilefrine, an adrenergic agent, has been used extensively for this purpose in Europe, but is not available in the United States. This and other agents with more limited anecdotal reports have been extensively reviewed, including flutamide and pentoxifylline.78
Chronic, monthly red blood cell transfusion is sometimes attempted prophylactically, but there is no substantial published evidence of efficacy for prevention of priapism.78 The medical management of recurrent or stuttering priapism is often difficult and frustrating, often involving sequential attempts with several different drugs, and clearly more rigorous clinical research is needed in this area. It is unfortunately common to have recurrent priapism subside only due to the development of impotence.4, 5557
Priapism is a frequent occurrence in males with SCD, but also seen in patients with other hemolytic disorders. Medical prophylaxis can be attempted in males with recurrent or stuttering priapism with hydroxyurea and pseudoephedrine, although supportive data are few. Etilefrine is not available in the United States, but there are reports of its prophylactic efficacy in Europe. There have been limited reports of effectiveness of leuprolide or diethylstilbestrol efficacy, but there are substantial reservations about their use. Previous dogmatic guidelines about medical management of acute sickle cell priapism have been questioned, and there is increased acceptance of early invasive urological management of acute severe priapism in SCD. Priapism is an important complication with substantial risk of long term consequences on sexual function. There are exciting recent advances in understanding its basic scientific mechanisms, but there still is a strong need for additional mechanistic research and cooperative clinical trials to improve the understanding, management and outcome of priapism.
Acknowledgments
Dr. Kato is supported by research funding from the Division of Intramural Research of the National Heart, Lung and Blood Institute at the National Institutes of Health (1ZIAHL006014-01 and others). He has received research funding through a Cooperative Research and Development agreement between the National Institutes of Health and Ikaria-INO Therapeutics.
Footnotes
He declares no conflicts of interest affecting any of the content of this manuscript.
1. Herrick JB. Peculiar elongated and sickle-shaped red blood corpuscles in a case of severe anemia. Arch Intern Med. 1910;6:517–21. [PMC free article] [PubMed]
2. Dawson GR., Jr Priapism: Report of Five Cases; Two Occurring with Sickle Cell Anemia. J Urol. 1939;42:821.
3. Sousa CM, Catoe BL, Scott RB. Studies in sickle cell anemia. XIX. Priapism as a complication in children. J Pediatr. 1962;60:52–4. [PubMed]
4. Gregory AB, Ates K, Trinity JB, Hussein G, Ajay N, Rany S. Priapism: Pathogenesis, Epidemiology, and Management. Journal of Sexual Medicine. 2010;7:476–500. [PubMed]
5. Broderick GA, Kadioglu A, Bivalacqua TJ, Ghanem H, Nehra A, Shamloul R. Priapism: pathogenesis, epidemiology, and management. J Sex Med. 2010;7:476–500. [PubMed]
6. Pauling L, Itano HA, Singer SJ, Wells IC. Sickle cell anemia, a molecular disease. Science. 1949;109:543. [PubMed]
7. Marotta CA, Forget BG, Cohne-Solal M, Wilson JT, Weissman SM. Human beta-globin messenger RNA. I. Nucleotide sequences derived from complementary RNA. Journal of Biological Chemistry. 1977;252:5019–31. [PubMed]
8. Frenette PS. Sickle Cell Vasoocclusion: Heterotypic, Multicellular Aggregations Driven by Leukocyte Adhesion. Microcirculation. 2004;11:167–77. [PubMed]
9. Brittain JE, Parise LV. The alpha4beta1 integrin in sickle cell disease. Transfus Clin Biol. 2008;15:19–22. [PubMed]
10. Gladwin MT, Schechter AN, Ognibene FP, Coles WA, Reiter CD, Schenke WH, Csako G, Waclawiw MA, Panza JA, Cannon RO., III Divergent nitric oxide bioavailability in men and women with sickle cell disease. Circulation. 2003;107:271–78. [PubMed]
11. Belhassen L, Pelle G, Sediame S, Bachir D, Carville C, Bucherer C, Lacombe C, Galacteros F, Adnot S. Endothelial dysfunction in patients with sickle cell disease is related to selective impairment of shear stress-mediated vasodilation. Blood. 2001;97:1584–89. [PubMed]
12. Eberhardt RT, McMahon L, Duffy SJ, Steinberg MH, Perrine SP, Loscalzo J, Coffman JD, Vita JA. Sickle cell anemia is associated with reduced nitric oxide bioactivity in peripheral conduit and resistance vessels. American Journal of Hematology. 2003;74:104–11. [PubMed]
13. Kaul DK, Liu XD, Fabry ME, Nagel RL. Impaired nitric oxide-mediated vasodilation in transgenic sickle mouse. American Journal of Physiology - Heart and Circulatory Physiology. 2000;278:H1799–H806. [PubMed]
14. Nath KA, Shah V, Haggard JJ, Croatt AJ, Smith LA, Hebbel RP, Katusic ZS. Mechanisms of vascular instability in a transgenic mouse model of sickle cell disease. American Journal of Physiology - Regulatory, Integrative, and Comparative Physiology. 2000;279:R1949–R55. [PubMed]
15. Setty BN, Stuart MJ. Vascular cell adhesion molecule-1 is involved in mediating hypoxia-induced sickle red blood cell adherence to endothelium: potential role in sickle cell disease. Blood. 1996;88:2311–20. [PubMed]
16. Kato GJ, Martyr S, Blackwelder WC, Nichols JS, Coles WA, Hunter LA, Brennan ML, Hazen SL, Gladwin MT. Levels of soluble endothelium-derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality. Br J Haematol. 2005;130:943–53. [PMC free article] [PubMed]
17. Duits AJ, Rojer RA, van Endt T, MacGillavry MR, ten Cate H, Brandjes DP, Schnog JB. Erythropoiesis and serum sVCAM-1 levels in adults with sickle cell disease. Annals of Hematology. 2003;82:171–74. [PubMed]
18. Conran N, Fattori A, Saad ST, Costa FF. Increased levels of soluble ICAM-1 in the plasma of sickle cell patients are reversed by hydroxyurea. American Journal of Hematology. 2004;76:343–47. [PubMed]
19. Ataga KI, Cappellini MD, Rachmilewitz EA. Beta-thalassaemia and sickle cell anaemia as paradigms of hypercoagulability. Br J Haematol. 2007;139:3–13. [PubMed]
20. Hebbel RP, Osarogiagbon R, Kaul D. The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy. Microcirculation. 2004;11:129–51. [PubMed]
21. Kato GJ, Gladwin MT. Evolution of novel small-molecule therapeutics targeting sickle cell vasculopathy. JAMA. 2008;300:2638–46. [PMC free article] [PubMed]
22. Landburg PP, Teerlink T, Biemond BJ, Brandjes DP, Muskiet FA, Duits AJ, Schnog JB. Plasma asymmetric dimethylarginine concentrations in sickle cell disease are related to the hemolytic phenotype. Blood Cells Mol Dis. 2010;44:229–32. [PubMed]
23. Ziaee SA, Javaherforooshzadeh A. Priapism in a 15-year-old boy with major beta-thalassemia. Urol J. 2008;5:55–6. [PubMed]
24. Sharma R, Prakash R, Kamboj S, Jain V. Hemoglobin-E beta thalassemia presenting with recurrent priapism--a rare complication. Am J Hematol. 2008;83:257. [PubMed]
25. Dore F, Bonfigli S, Pardini S, Pirozzi F, Longinotti M. Priapism in thalassemia intermedia. Haematologica. 1991;76:523. [PubMed]
26. Macchia P, Massei F, Nardi M, Favre C, Brunori E, Barba V. Thalassemia intermedia and recurrent priapism following splenectomy. Haematologica. 1990;75:486–87. [PubMed]
27. Jackson N, Franklin IM, Hughes MA. Recurrent priapism following splenectomy for thalassaemia intermedia. Br J Surg. 1986;73:678. [PubMed]
28. Rao KR, Patel AR. Priapism and thalassaemia intermedia. British Journal of Surgery. 1986;73:1048. [PubMed]
29. Andrieu V, Dumonceau O, Grange MJ. Priapism in a patient with unstable hemoglobin: hemoglobin Koln. American Journal of Hematology. 2003;74:73–74. [PubMed]
30. Gyan E, Darre S, Jude B, Cambier N, Demory JL, Bauters F, Rose C. Acute priapism in a patient with unstable hemoglobin Perth and Factor V Leiden under effective oral anticoagulant therapy. Hematol J. 2001;2:210–11. [PubMed]
31. Thuret I, Bardakdjian J, Badens C, Wajcman H, Galacteros F, Vanuxem D, Perrimond H, Giraud F, Lena-Russo D. Priapism following splenectomy in an unstable hemoglobin: hemoglobin Olmsted beta 141 (H19) Leu-->Arg. Am J Hematol. 1996;51:133–36. [PubMed]
32. Finley DS. Glucose-6-phosphate dehydrogenase deficiency associated stuttering priapism: report of a case. J Sex Med. 2008;5:2963–6. [PubMed]
33. Burnett AL, Bivalacqua TJ. Glucose-6-phosphate dehydrogenase deficiency: an etiology for idiopathic priapism? J Sex Med. 2008;5:237–40. [PubMed]
34. Goulding FJ. Priapism caused by glucose phosphate isomerase deficiency. Journal of Urology. 1976;116:819–20. [PubMed]
35. Edney MT, Schned AR, Cendron M, Chaffee S, Ellsworth PI. Priapism in a 15-year-old boy with congenital dyserythropoietic anemia type II (hereditary erythroblastic multinuclearity with positive acidified serum lysis test) J Urol. 2002;167:309–10. [PubMed]
36. Atala A, Amin M, Harty JI, Liu YK, Keeling MM. Priapism associated with asplenic state. Urology. 1992;40:371–3. [PubMed]
37. Gross EM, Levin PD, Landau EH. Post-splenectomy veno-occlusive priapism in a child with idiopathic thrombocytopenic purpura. Isr Med Assoc J. 2002;4:1084–5. [PubMed]
38. Westerman M, Pizzey A, Hirschman J, Cerino M, Weil-Weiner Y, Ramotar P, Eze A, Lawrie A, Purdy G, Mackie I, Porter J. Microvesicles in haemoglobinopathies offer insights into mechanisms of hypercoagulability, haemolysis and the effects of therapy. Br J Haematol. 2008;142:126–35. [PubMed]
39. Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Reviews. 2007;21:37–47. [PMC free article] [PubMed]
40. Kato GJ, Taylor JGt. Pleiotropic effects of intravascular haemolysis on vascular homeostasis. Br J Haematol. 2010;148:690–701. [PMC free article] [PubMed]
41. Reiter CD, Wang X, Tanus-Santos JE, Hogg N, Cannon RO, III, Schechter AN, Gladwin MT. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nature medicine. 2002;8:1383–89. [PubMed]
42. Wood KC, Hsu LL, Gladwin MT. Sickle cell disease vasculopathy: A state of nitric oxide resistance. Free Radic Biol Med. 2008;44:1506–28. [PubMed]
43. Morris CR, Kato GJ, Poljakovic M, Wang X, Blackwelder WC, Sachdev V, Hazen SL, Vichinsky EP, Morris SM, Jr, Gladwin MT. Dysregulated Arginine Metabolism, Hemolysis-Associated Pulmonary Hypertension and Mortality in Sickle Cell Disease. JAMA. 2005;294:81–90. [PMC free article] [PubMed]
44. Aslan M, Ryan TM, Adler B, Townes TM, Parks DA, Thompson JA, Tousson A, Gladwin MT, Patel RP, Tarpey MM, Batinic-Haberle I, White CR, Freeman BA. Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease. Proc Natl Acad Sci USA. 2001;98:15215–20. [PubMed]
45. Repka T, Hebbel RP. Hydroxyl radical formation by sickle erythrocyte membranes: role of pathologic iron deposits and cytoplasmic reducing agents. Blood. 1991;78:2753–58. [PubMed]
46. Hebbel RP, Eaton JW, Balasingam M, Steinberg MH. Spontaneous oxygen radical generation by sickle erythrocytes. Journal of Clinical Investigation. 1982;70:1253–59. [PMC free article] [PubMed]
47. Kato GJ, Wang Z, Machado RF, Blackwelder WC, Taylor JGt, Hazen SL. Endogenous nitric oxide synthase inhibitors in sickle cell disease: abnormal levels and correlations with pulmonary hypertension, desaturation, haemolysis, organ dysfunction and death. Br J Haematol. 2009;145:506–13. [PMC free article] [PubMed]
48. Nolan VG, Adewoye A, Baldwin C, Wang L, Ma Q, Wyszynski DF, Farrell JJ, Sebastiani P, Farrer LA, Steinberg MH. Sickle cell leg ulcers: associations with haemolysis and SNPs in Klotho, TEK and genes of the TGF-beta/BMP pathway. Br J Haematol. 2006;133:570–78. [PMC free article] [PubMed]
49. Gladwin MT, Sachdev V, Jison ML, Shizukuda Y, Plehn JF, Minter K, Brown B, Coles WA, Nichols JS, Ernst I, Hunter LA, Blackwelder WC, Schechter AN, Rodgers GP, Castro O, Ognibene FP. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. New Engl J Med. 2004;350:886–95. [PubMed]
50. Gladwin MT, Vichinsky E. Pulmonary complications of sickle cell disease. N Engl J Med. 2008;359:2254–65. [PubMed]
51. Bunn HF, Nathan DG, Dover GJ, Hebbel RP, Platt OS, Rosse WF, Ware RE. Pulmonary hypertension and nitric oxide depletion in sickle cell disease. Blood. 2010;116:687–92. [PubMed]
52. Montalban J, Lozano P, Lu L, Gonzalez A. Paroxysmal nocturnal hemoglobinuria and priapism. Med Clin (Barc) 1986;87:394. [PubMed]
53. Brodsky RA. Advances in the diagnosis and therapy of paroxysmal nocturnal hemoglobinuria. Blood Rev. 2008;22:65–74. [PMC free article] [PubMed]
54. Bennett N, Mulhall J. Sickle cell disease status and outcomes of African-American men presenting with priapism. J Sex Med. 2008;5:1244–50. [PubMed]
55. Adetayo FO. Outcome of management of acute prolonged priapism in patients with homozygous sickle cell disease. West Afr J Med. 2009;28:234–9. [PubMed]
56. Pohl J, Pott B, Kleinhans G. Priapism: a three-phase concept of management according to aetiology and prognosis. Br J Urol. 1986;58:113–8. [PubMed]
57. Winter CC, McDowell G. Experience with 105 patients with priapism: update review of all aspects. J Urol. 1988;140:980–3. [PubMed]
58. Mantadakis E, Cavender JD, Rogers ZR, Ewalt DH, Buchanan GR. Prevalence of priapism in children and adolescents with sickle cell anemia. Journal of Pediatric Hematology/Oncology. 1999;21:518–22. [PubMed]
59. Al-Awamy B, Taha SA, Naeem MA. Priapism in association with sickle cell anemia in Saudi Arabia. Acta Haematol. 1985;73:181–2. [PubMed]
60. Christakis J, Vavatsi N, Hassapopoulou H, Papadopoulou M, Mandraveli K, Loukopoulos D, Morris JS, Serjeant BE, Serjeant GR. Comparison of homozygous sickle cell disease in northern Greece and Jamaica. Lancet. 1990;335:637–40. [PubMed]
61. Nolan VG, Wyszynski DF, Farrer LA, Steinberg MH. Hemolysis-associated priapism in sickle cell disease. Blood. 2005;106:3264–67. [PubMed]
62. Kato GJ, McGowan V, Machado RF, Little JA, Taylor Jt, Morris CR, Nichols JS, Wang X, Poljakovic M, Morris SM, Jr, Gladwin MT. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood. 2006;107:2279–85. [PubMed]
63. Adedeji MO, Onuora VC, Ukoli FA. Haematological parameters associated with priapism in Nigerian patients with homozygous sickle cell disease. J Trop Med Hyg. 1988;91:157–9. [PubMed]
64. Sharpsteen JR, Jr, Powars D, Johnson C, Rogers ZR, Williams WD, Posch RJ. Multisystem damage associated with tricorporal priapism in sickle cell disease. Am J Med. 1993;94:289–95. [PubMed]
65. Halabi-Tawil M, Lionnet F, Girot R, Bachmeyer C, Levy PP, Aractingi S. Sickle cell leg ulcers: a frequently disabling complication and a marker of severity. Br J Dermatol. 2008;158:339–44. [PubMed]
66. Nolan VG, Baldwin C, Ma Q, Wyszynski DF, Amirault Y, Farrell JJ, Bisbee A, Embury SH, Farrer LA, Steinberg MH. Association of single nucleotide polymorphisms in klotho with priapism in sickle cell anaemia. Br J Haematol. 2005;128:266–72. [PubMed]
67. Elliott L, Ashley-Koch AE, De Castro L, Jonassaint J, Price J, Ataga KI, Levesque MC, Brice Weinberg J, Eckman JR, Orringer EP, Vance JM, Telen MJ. Genetic polymorphisms associated with priapism in sickle cell disease. British journal of haematology. 2007;137:262–7. [PubMed]
68. Kaul DK. Sickle red cell adhesion: many issues and some answers. Transfus Clin Biol. 2008;15:51–5. [PubMed]
69. Burnett AL, Chang AG, Crone JK, Huang PL, Sezen SE. Noncholinergic penile erection in mice lacking the gene for endothelial nitric oxide synthase. J Androl. 2002;23:92–7. [PubMed]
70. Champion HC, Bivalacqua TJ, Takimoto E, Kass DA, Burnett AL. Phosphodiesterase-5A dysregulation in penile erectile tissue is a mechanism of priapism. Proc Natl Acad Sci USA. 2005;102:1661–66. [PubMed]
71. Hedlund P, Aszodi A, Pfeifer A, Alm P, Hofmann F, Ahmad M, Fassler R, Andersson KE. Erectile dysfunction in cyclic GMP-dependent kinase I-deficient mice. Proceedings of the National Academy of Sciences of the United States of America. 2000;97:2349–54. [PubMed]
72. Bivalacqua TJ, Musicki B, Hsu LL, Gladwin MT, Burnett AL, Champion HC. Establishment of a transgenic sickle-cell mouse model to study the pathophysiology of priapism. J Sex Med. 2009;6:2494–504. [PubMed]
73. Claudino MA, Franco-Penteado CF, Corat MA, Gimenes AP, Passos LA, Antunes E, Costa FF. Increased cavernosal relaxations in sickle cell mice priapism are associated with alterations in the NO-cGMP signaling pathway. J Sex Med. 2009;6:2187–96. [PubMed]
74. Mi T, Abbasi S, Zhang H, Uray K, Chunn JL, Xia LW, Molina JG, Weisbrodt NW, Kellems RE, Blackburn MR, Xia Y. Excess adenosine in murine penile erectile tissues contributes to priapism via A2B adenosine receptor signaling. J Clin Invest. 2008;118:1491–501. [PMC free article] [PubMed]
75. Wen J, Jiang X, Dai Y, Zhang Y, Tang Y, Sun H, Mi T, Kellems RE, Blackburn MR, Xia Y. Adenosine deaminase enzyme therapy prevents and reverses the heightened cavernosal relaxation in priapism. J Sex Med. 2010;7:3011–22. [PMC free article] [PubMed]
76. Wen J, Jiang X, Dai Y, Zhang Y, Tang Y, Sun H, Mi T, Phatarpekar PV, Kellems RE, Blackburn MR, Xia Y. Increased adenosine contributes to penile fibrosis, a dangerous feature of priapism, via A2B adenosine receptor signaling. FASEB J. 24:740–9. [PubMed]
77. Fowler JE, Jr, Koshy M, Strub M, Chinn SK. Priapism associated with the sickle cell hemoglobinopathies: prevalence, natural history and sequelae. J Urol. 1991;145:65–68. [PubMed]
78. Rogers ZR. Priapism in sickle cell disease. Hematology/Oncology Clinics of North America. 2005;19:917–28. [PubMed]
79. Merritt AL, Haiman C, Henderson SO. Myth: blood transfusion is effective for sickle cell anemia-associated priapism. CJEM. 2006;8:119–22. [PubMed]
80. Siegel JF, Rich MA, Brock WA. Association of sickle cell disease, priapism, exchange transfusion and neurological events: ASPEN syndrome. J Urol. 1993;150:1480–82. [PubMed]
81. Rackoff WR, Ohene-Frempong K, Month S, Scott JP, Neahring B, Cohen AR. Neurologic events after partial exchange transfusion for priapism in sickle cell disease. J Pediatr. 1992;120:882–85. [PubMed]
82. Mantadakis E, Ewalt DH, Cavender JD, Rogers ZR, Buchanan GR. Outpatient penile aspiration and epinephrine irrigation for young patients with sickle cell anemia and prolonged priapism. Blood. 2000;95:78–82. [PubMed]
83. Saad ST, Lajolo C, Gilli S, Marques Junior JF, Lima CS, Costa FF, Arruda VR. Follow-up of sickle cell disease patients with priapism treated by hydroxyurea. American Journal of Hematology. 2004;77:45–49. [PubMed]
84. Al Jam'a AH, Al Dabbous IA. Hydroxyurea in the treatment of sickle cell associated priapism. J Urol. 1998;159:1642. [PubMed]
85. Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, Orringer E, Bellevue R, Olivieri N, Eckman J, Varma M, Ramirez G, Adler B, Smith W, Carlos T, Ataga K, DeCastro L, Bigelow C, Saunthararajah Y, Telfer M, Vichinsky E, Claster S, Shurin S, Bridges K, Waclawiw M, Bonds D, Terrin M. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 2003;289:1645–51. [PubMed]
86. Steinberg MH, McCarthy WF, Castro O, Ballas SK, Armstrong FD, Smith W, Ataga K, Swerdlow P, Kutlar A, DeCastro L, Waclawiw MA. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. Am J Hematol. 2010;85:403–8. [PMC free article] [PubMed]
87. Burnett AL, Bivalacqua TJ, Champion HC, Musicki B. Feasibility of the use of phosphodiesterase type 5 inhibitors in a pharmacologic prevention program for recurrent priapism. J Sex Med. 2006;3:1077–84. [PubMed]
88. Bialecki ES, Bridges KR. Sildenafil relieves priapism in patients with sickle cell disease. Am J Med. 2002;113:252. [PubMed]
89. Tzortzis V, Mitrakas L, Gravas S, Mamoulakis C, Meissner A, Kyriakou D, Melekos MD. Oral phosphodiesterase type 5 inhibitors alleviate recurrent priapism complicating thalassemia intermedia: a case report. J Sex Med. 2009;6:2068–71. [PubMed]
90. Levine LA, Guss SP. Gonadotropin-releasing hormone analogues in the treatment of sickle cell anemia-associated priapism. J Urol. 1993;150:475–77. [PubMed]
91. Serjeant GR, De Ceulaer K, Maude GH. Stilboestrol and stuttering priapism in homozygous sickle-cell disease. Lancet. 1985;2:1274–76. [PubMed]
92. Schilling RF, Gangnon RE, Traver MI. Delayed adverse vascular events after splenectomy in hereditary spherocytosis. J Thromb Haemost. 2008;6:1289–95. [PubMed]
93. Prabhakaran K, Jacobs BL, Smaldone MC, Franks ME. Stuttering priapism associated with hereditary spherocytosis. Can J Urol. 2007;14:3702–04. [PubMed]
94. Wen J, Jiang X, Dai Y, Zhang Y, Tang Y, Sun H, Mi T, Phatarpekar PV, Kellems RE, Blackburn MR, Xia Y. Increased adenosine contributes to penile fibrosis, a dangerous feature of priapism, via A2B adenosine receptor signaling. Faseb J. 2010;24:740–9. [PubMed]
95. Merritt AL, Haiman C, Henderson SO. Myth: blood transfusion is effective for sickle cell anemia-associated priapism. CJEM. 2006;8:119–22. [PubMed]
96. Costabile RA. Successful treatment of stutter priapism with an antiandrogen. Techniques in Urology. 1998;4:167–68. [PubMed]
97. Gbadoe AD, Assimadi JK, Segbena YA. Short period of administration of diethylstilbestrol in stuttering priapism in sickle cell anemia. American Journal of Hematology. 2002;69:297–98. [PubMed]
98. Karayalcin G, Imran M, Rosner F. Priapism in sickle cell disease: report of five cases. American Journal of the Medical Sciences. 1972;264:289–93. [PubMed]
99. Erman S, Bloomberg HH. Priapism in sickle cell anemia: treatment by estrogenic hormone. J Urol. 1960;84:345–6. [PubMed]
100. Okpala I, Westerdale N, Jegede T, Cheung B. Etilefrine for the prevention of priapism in adult sickle cell disease. British journal of haematology. 2002;118:918–21. [PubMed]
101. Gbadoe AD, Atakouma Y, Kusiaku K, Assimadi JK. Management of sickle cell priapism with etilefrine. Arch Dis Child. 2001;85:52–53. [PMC free article] [PubMed]